Back to search results

Cognitive Biomarkers in Pediatric Brain Tumor Patients

This study is looking at how brain tumors affect thinking and learning abilities in children. Researchers will use neurocognitive testing (tests of memory, attention, etc.) and a special type of MRI called rsfcMRI (resting-state functional connectivity MRI) to understand these changes. The goal is to find early signs that can predict how a child's thinking skills will be affected and how they might recover. You might be able to join if you are between 4 and 18 years old and have a newly diagnosed brain tumor. The study aims to enroll 200 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 200 participants. It involves three cohorts of patients.
What's involved
Participants will undergo neurocognitive testing and rsfcMRI scans. The study will track cognitive outcomes for up to 27 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 27 months to assess cognitive recovery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02914067

Cognitive Biomarkers in Pediatric Brain Tumor Patients

Recruiting
NAAges 4–18Interventional
Washington University School of Medicine
~200 participants
Updated 2025-11-21 on ClinicalTrials.gov
What's tested:Neurocognitive testingrsfcMRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify reliable peri-diagnostic estimators of cognition as measured by neurocognitive testing
Measured over Peri-diagnostic period (from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later)
+4 more outcomes measured

Conditions

Childhood Brain Tumor

Explore related trials

Brain Neoplasm

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Stephanie Perkins, M.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine

Who to contact

Stephanie Perkins, M.D.
[email protected]
314-273-2931
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Between 4 and 18 years of age, inclusive
Newly diagnosed primary brain tumor of any location and any histology
Life expectancy of at least one year
Able to understand and willing to consent or assent to the research proposed, along with consent of legal guardian(s) if applicable
Between 4 and 18 years of age, inclusive
Previous diagnosis of a posterior fossa brain tumor; patients who are either undergoing active treatment for posterior fossa tumor or who have completed treatment will be eligible for study enrollment
Life expectancy of at least one year
Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable
Between 4 and 18 years of age, inclusive
Previous diagnosis of a posterior fossa brain tumor
Clinical diagnosis of post-operative posterior fossa syndrome
Inability to complete NIH Toolbox
Life expectancy of at least one year
Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable
Between 12-30 years of age, inclusive
Diagnosis of a brain tumor \>3 years prior to study enrollment
Life expectancy of at least one year
Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable
Patient must be able to complete a 1 hour MRI scan without sedation

Exclusion

Presence of visual impairment to an extent that the patient is unable to complete the computer testing
Contraindication to MRI scan (i.e. due to cardiac pacemaker)
Programmable Shunt
Presence of visual impairment to an extent that the patient is unable to complete the computer testing
Contraindication to MRI scan (i.e. due to cardiac pacemaker)
Contraindication to MRI scan (i.e. due to cardiac pacemaker)
Contraindiciation to MRI scan (i.e. due to cardian pacemaker)
Presence of dental braces or programmable shunt
Patient requires sedation for MRI scan

What this trial measures

  • Identify reliable peri-diagnostic estimators of cognition as measured by neurocognitive testingPeri-diagnostic period (from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later)
  • Identify reliable peri-diagnostic estimators of cognition as measured by advanced resting-state functional connectivity MRI (rsfcMRI) dataPeri-diagnostic period (from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later)
  • Predictors of cognitive recovery in children as determined by multiplexed analyses of a combination of potential biomarkers across multiple modalities (rsfcMRI, structural MRI, NIH Toolbox, patient demographics, treatment information)Up to 27 months

    As dictated by information theory, properly combining predictors across modalities must increase the accuracy of the prediction algorithm, unless a given modality contains no information about the question of interest (in this case, long-term cognitive outcomes).

  • Identify reliable peri-diagnostic estimators of brain function as measured by neurocognitive testingPeri-diagnostic period (from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later)
  • Identify reliable peri-diagnostic estimators of brain function as measured by advanced resting-state functional connectivity MRI (rsfcMRI) dataPeri-diagnostic period (from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later)